Justin Wolfe
Co-Founder & Chief Scientific Officer Transcera Inc.
Seminars
Thursday 30th October 2025
Harnessing Sphingolipid Biology for Targeted Degradation of Extracellular Proteins
1:00 pm
- Building on fundamental discoveries in sphingolipid biology, Transcera develop a new modality for extracellular protein degradation that harness native ceramide trafficking pathways
- Transcera’s degraders work across multiple cell types in tissues throughout the body, have extended half-life for durable target depletion, and are simple to manufacture
- Transcera has a rapidly advancing pipeline focused on immune disorders
- We aim to transform the treatment landscape for chronic diseases driven by extracellular proteins
